Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

After that technology had proven its worth, the full-blown virtual hospital was launched by the Saudi ministry of health in ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

Discover eight promising respiratory disease companies advancing their novel therapies through clinical trials in 2025.

Market OverviewThe Lung In Vitro Model Market has been experiencing significant growth, driven by advancements in ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

Background Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus ...

Among those with chronic medical conditions, a third (33 percent) either had no concerns about developing shingles or were ...

The Cambridge Festival is returning from March 19 to April 4 with a series of events that bring together cutting-edge health ...

A global elderly and aging population has significant impacts, not only in terms of individual health risk but in terms of ...